Accéder au contenu
Merck

Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.

European journal of medicinal chemistry (2021-09-13)
Manon Sturbaut, Fabrice Bailly, Mathilde Coevoet, Pasquale Sileo, Martine Pugniere, Maxime Liberelle, Romain Magnez, Xavier Thuru, Marie-Christine Chartier-Harlin, Patricia Melnyk, Muriel Gelin, Frédéric Allemand, Jean-François Guichou, Philippe Cotelle
RÉSUMÉ

The Hippo pathway is involved in organ size control and tissue homeostasis by regulating cell growth, proliferation and apoptosis. It controls the phosphorylation of the transcription co-activator YAP (Yes associated protein) and TAZ (Transcriptional coactivator with PDZ-binding motif) in order to control their nuclear import and their interaction with TEAD (Transcriptional Enhanced Associated Domain). YAP, TAZ and TEADs are dysregulated in several cancers making YAP/TAZ-TEAD interaction a new emerging anti-cancer target. We report the synthesis of a set of trisubstituted pyrazoles which bind to hTEAD2 at the interface 2 revealing for the first time a cryptic pocket created by the movement of the phenol ring of Y382. Compound 6 disrupts YAP/TAZ-TEAD interaction in HEK293T cells and inhibits TEAD target genes and cell proliferation in MDA-MB-231 cells. Compound 6 is therefore the first inhibitor of YAP/TAZ-TEAD targeting interface 2. This molecule could serve with other pan-TEAD inhibitors such as interface 3 ligands, for the delineation of the relative importance of VGLL vs YAP/TAZ in a given cellular model.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
VT107, ≥98% (HPLC)